Association of a CYP17 gene polymorphism with development of breast cancer in India

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1653-1657

  Surekha, D ^a   Sailaja, K ^a   Rao, D Nageswara ^a   Padma, T ^a   Raghunadharao, D ^b   Vishnupriya, S ^a  

^a OSMANIA UNIVERSITY   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Breast cancer; CYP17; India; PCR RFLP; Receptor status

Indexed keywords

EID: 79956153009     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bergman-Jungestrom M, Gentile M, Lundin AC, et al (1999). Association between CYP17 polymorphism and risk of breast cancer in young women. Int J cancer, 84, 350-3.
2. Carey AH, Waterworth D, Patel K, et al (1994). Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet, 3, 1873-6.
3. Chakraborty A, Murthy NS, Chintamani C, et al (2007). Cyp17 gene polymorphism and its association with high-risk north Indian breast cancer patients. Hum Gent, 52, 159-65.
4. Dunning AM, Healey CS, Pharoah PDP, et al (1998). No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer, 77, 2045-7.
5. Dunning AM, Healey CS, Pharoah PDP, et al (1998). A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 8, 843-54.
6. Fan YS, Sasi R, Lee C, et al (1992). Localization of the human CYP17 gene to 10q24.3 by fluorescence insitu hybridization and simultaneous chromosome banding. Genomics, 14, 1110-1.
7. Feigelson HS, Henderson BE (1996). Estrogen and breast cancer. Carcinogenesis, 17, 2279-84.
8. Feigelson HS, Coetzee GA, Kolonel LN, et al (1997). A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57, 1063-5.
9. Feigelson HS, Mc Kean-Cowdin R, Pike MC, et al (1998). Cytochrome P450c17α (CYP17) polymorphism is associate with serum estrogen and progesterone concentration. Cancer Res, 58, 585-7.
10. Feigelson HS, Mc Kean-Cowdin, Henderson BE (2002). Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta analysis. Mutagenesis, 17, 445-6.
11. Habuchi T, Liging Z, Suzuki T, et al (2000). In creased risk of prostrate cancer and benign prostratic hyperplasia associated with CYP17 gene polymorphism with a gene dosage effect. Cancer Res, 60, 5710-3.
12. Haiman CA, Hankinson SE, Spieglman D, et al (1999). The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res, 59, 1015-20.
13. Huang CS, Chern HD, Chang KJ, et al (1999). Breast cancer risk association with genotype polymorphism of the estrogen -metabolizing genes CYP17, CYP1A1 and COMT: A multigenic study on cancer susceptibility. Cancer Res, 59, 4870-5.
14. Lahiri DK, Nurnberger JI Jr (1991). A rapid non-enzymatic method for the preparation of HMW from blood RFLP studies. Nucleic Acid Research, 19, 5444.
15. Lo SF, Huang CM, Lin HC (2004). Association of CYP17 gene polymorphism and rheumatoid arthritis in chinese patients in central Taiwan. Rheumatol Int, 25, 580-4.
16. Miteunen K, Jourenkova N, Kataja V, et al (2000). Steriod metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev, 9, 1343-8.
17. McKean-Cowdin R, Feigelson HS, Pike MC, et al (2001). Risk of endometrial cancer and estrogen replacement therapy history by cyp17 genotype. Cancer Research, 61, 848-9.
18. Service RF (1998). New role for estrogen in cancer? Science (Wash), 279, 631-3.
19. Spurdle AB, Hopper JL, Dite GS, et al (2000). CYP17 promoter polymorphism and breast cancer in Australian women under age fourty years. J National Cancer Ins, 92, 1674-81.
20. Wadelius M, Andersson AO, Johansson JE, et al (1999). Prostrate cancer associated with CYP17 genotype. Pharmacogenetics, 9, 635-9.
21. Weber BL, Nathanson KL (2000). Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer, 36, 1193-9.
22. Weston A, Pan CF, Bleiweiss IJ, et al (1998). CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarl Prev, 7, 941-5.
23. Zhu BT, Conney AH (1998). Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res, 58, 2269-77.